Emergence Therapeutics Launched to Develop Novel ADC Immuno-therapies to Treat High-need Cancers

Focus on best combination of validated targets and ADC technology to tackle hard to treat cancers

Duisburg, Germany – Marseille, France, 1 October 2019: Emergence Therapeutics AG today announced its incorporation by founders Jack Elands, Xavier Preville and Kurma Partners. Emergence Therapeutics is a new pan-European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high unmet need cancers. The company is based in Duisburg, Germany with a subsidiary in Marseille, France.

Dr. Jack Elands, Chief Executive Officer commented: “Recent developments show that ADC technology is maturing. ADCs now represent a significant opportunity to treat solid cancers of high unmet medical need. Emergence Therapeutics’ strategy is to develop novel ADCs to treat such cancers by selecting the best combination of validated targets and ADC technology. The company is completing the process of in-licensing key assets to embark on its first program.”

Dr. Peter Neubeck, investment director at Kurma partners added: “As an investor in early-stage opportunities Kurma is proud to be a co-founder of Emergence Therapeutics and help the company to secure further investments towards its goal of developing novel ADCs.”

Latest News


Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal

Synaffix to provide access to proprietary ADC technologies (GlycoConnect™, HydraSpace™ and exatecan-based SYNtecan E™ linker-payload) Emergence Therapeutics secures rights to develop multiple ADCs against undisclosed targets to strengthen its ADC pipeline Emergence Therapeutics becomes the tenth company to license the Synaffix ADC technology platform in a deal with a total potential value of up to...

View Article >

Emergence Therapeutics strengthens leadership team with the appointment of Hatem Azim as Chief Medical Officer

Duisburg, Germany, 7 June 2022. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces the appointment of Hatem Azim, MD, PhD, as Chief Medical Officer (“CMO”), as of 6 June 2022. Dr. Hatem Azim joins Emergence Therapeutics from Pierre Fabre, a...

View Article >

Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC

Series A round led by Pontifax and includes new and existing investors Lead product is a next-generation Nectin-4 ADC designed to increase efficacy and minimize toxicity Strategy is to become a dominant ADC developer   Duisburg, Germany, 7 December 2021. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment...

View Article >